OncoMatch/Clinical Trials/NCT04719156
Fluorescent Intra-operative Tumor Margin Examination
Is NCT04719156 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Indocyanine green solution administered at 2.0mg/kg. and Stryker SPY-PHI Imaging Device for sarcoma.
Treatment: Indocyanine green solution administered at 2.0mg/kg. · Stryker SPY-PHI Imaging Device — Tumor margin confirmation is important to confirming appropriate disease excision. Current standard of care is to take select margin samples to pathology for intra-operative readings. However, this is expensive, time consuming, and only assesses the margin contained within the specific sample. In prior work the investigators have determined that indocyanine green (ICG) is highly specific to the tumor bed when injected shortly before surgery. The investigators hypothesize that ICG will be able to accurately identify residual positive tumor margins during sarcoma excision procedures.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Demographics
Prior therapy
Cannot have received: surgery
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UPMC-Shadyside Hospital · Pittsburgh, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04719156 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior surgery disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 100 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages